James Huang
CIK 1573160 · Chief Executive Officer · last filed 2026-06-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$30.09M
Companies
7
Total Filings
44
Lifetime Open-Market Net
$8.60M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CNTB | Director | 13,310,000 | $2.08 | $27.68M | $4.37M | 2 | 2026-06-02 |
| ATRA | Director | 307,894 | $7.81 | $2.40M | -$4.99M | 3 | 2026-05-11 |
| TCRT | Director | 1,256 | $1.90 | $2.4K | $0 | 3 | 2023-06-08 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) Delisted | Director | 84 | $0.01 | $1 | $7.73M | 17 | 2023-02-23 |
| CASI Pharmaceuticals, Inc. (CASI) Delisted | Director | 371,708 | $0.28 | $104.1K | $1.32M | 14 | 2022-09-08 |
| Alaunos Therapeutics, Inc. (ZIOP) Delisted | Director | 108,333 | $0.87 | $93.8K | $171.0K | 3 | 2021-09-03 |
| CASI Pharmaceuticals, Inc. (ENMD) Delisted | Director | — | — | — | $0 | 1 | 2013-05-31 |
Recent Filings · Page 2 of 5
44 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-08-26 | CASI Pharmaceuticals, Inc. (CASI) Delisted | Buy (P) | +44,527 | $166.9K | EDGAR |
| 2022-08-23 | CASI Pharmaceuticals, Inc. (CASI) Delisted | Buy (P) | +234,221 | $779.5K | EDGAR |
| 2022-06-24 | TCRT | Grant (A) | +80,000 | $0 | EDGAR |
| 2022-06-24 | TCRT | Grant (A) | +80,000 | $0 | EDGAR |
| 2022-06-09 | WINDTREE THERAPEUTICS INC /DE/ (WINT) Delisted | Grant (A) | +5,000 | $0 | EDGAR |
| 2022-05-26 | CASI Pharmaceuticals, Inc. (CASI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-10-19 | WINDTREE THERAPEUTICS INC /DE/ (WINT) Delisted | Buy (P) | +50,000 | $95.1K | EDGAR |
| 2021-09-03 | Alaunos Therapeutics, Inc. (ZIOP) Delisted | Buy (P) | +100,000 | $171.0K | EDGAR |
| 2021-06-17 | WINDTREE THERAPEUTICS INC /DE/ (WINT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-16 | CASI Pharmaceuticals, Inc. (CASI) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.